Related Experiment Video
Updated: Mar 15, 2026
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Reduced Susceptibility to Cefepime-Taniborbactam in Carbapenem-Resistant Klebsiella pneumoniae Attributed to
Baofang Zhang1,2, Wei Xu3, Xiaoxia Zhang4
1Depatment of Infectious Diseases, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Background:
The recent emergence of a carbapenem-resistant Klebsiella pneumoniae (CRKP) strain from a clinical specimen resistant to cefepime-taniboractam (FEP-TAN) raises serious concerns, necessitating further investigation of its resistance mechanisms.
Methods:
Three CRKP clinical isolates were investigated: 1 FEP-TAN-resistant colonizing strain (CRKP068) from a throat swab of a patient with lung infection and 2 FEP-TAN-sensitive controls (CRKP288 and CRKP170141). Whole-genome sequencing and clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9-mediated mutagenesis of the ftsI gene, encoding penicillin-binding protein 3 (PBP3), in the FEP-TAN-sensitive CRKP288 were used to generate isogenic mutants and confirm that PBP3 alterations were responsible for the resistance.
Results:
The concurrent Asp76Val/Ala498Val substitutions in PBP3 conferred FEP-TAN resistance in the mutants while inducing filamentous morphology and membrane permeability defects. These mutations also reduced bacterial fitness, evidenced by decreased growth rates (k) under nutrient limitation, suggesting a tradeoff between resistance and proliferative capacity.
Conclusions:
Although PBP3-mediated FEP-TAN resistance entails measurable fitness costs, especially under nutrient-limited conditions, PBP3 polymorphism surveillance should be incorporated into resistance monitoring.
More Related Videos
Related Concept Videos
01:30Development of Antibiotic Resistance
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...